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Obeticholic acid for the treatment of primary 
biliary cholangitis in adult patients: clinical utility 
and patient selection
Christopher L Bowlus
Division of Gastroenterology and 
Hepatology, University of California 
Davis, Davis, CA, USA
Abstract: Primary biliary cholangitis (PBC), previously known as primary biliary “cirrhosis”, 
is a rare autoimmune liver disease characterized by the hallmark autoantibodies to mitochon-
drial antigens and immune-mediated destruction of small bile duct epithelial cells leading to 
cholestasis and cirrhosis. Surprisingly, while immune modulators have not been effective in 
the treatment of PBC, supplementation with the hydrophilic bile acid (BA) ursodeoxycholic 
acid (UDCA) has been demonstrated to slow the disease progression. However, a significant 
minority of PBC patients do not have a complete response to UDCA and remain at risk of 
continued disease progression. Although the mechanisms of action are not well understood, 
UDCA provided proof of concept for BA therapy in PBC. Obeticholic acid (OCA), a novel 
derivative of the human BA chenodeoxycholic acid, is a potent agonist of the nuclear hormone 
receptor farnesoid X receptor, which regulates BA synthesis and transport. A series of clinical 
trials of OCA in PBC, primarily in combination with UDCA, have established that OCA leads 
to significant reductions in serum alkaline phosphatase that are predicted to lead to improved 
clinical outcomes, while dose-dependent pruritus has been the most common adverse effect. 
On the basis of these studies, OCA was given conditional approval by the US Food and Drug 
Administration with plans to establish the long-term clinical efficacy of OCA in patients with 
advanced PBC.
Keywords: primary biliary cholangitis, nuclear receptors, farnesoid X receptor, bile acid, 
obeticholic acid, ursodeoxycholic acid
Primary biliary cholangitis
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is a 
chronic cholestatic liver disease with an autoimmune basis, affecting mostly middle-
aged women.1 The inflammatory response leads to slow destruction of small intrahepatic 
bile ducts and progression at varying rates to cirrhosis leading to liver transplantation 
or death.2 PBC is typically suspected in asymptomatic patients when cholestatic liver 
biochemistries are encountered, as part of the evaluation of symptoms related to cho-
lestasis such as pruritus, or during the evaluation of cirrhosis. The diagnosis of PBC 
requires fulfillment of at least two of three criteria including an elevated serum alkaline 
phosphatase (ALP), the presence of antimitochondrial antibodies (AMA), and liver 
histology compatible with PBC. Because AMA is detected in 90%–95% of patients 
with PBC and in less than 1% of normal controls, liver biopsy is rarely required for the 
diagnosis of PBC.3 In addition to diagnosis, liver biopsy was historically used for staging 
of fibrosis but has been replaced by noninvasive methods such as transient elastography.
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The immunopathology of PBC is well understood.4 The 
major targets of the AMA have been identified and include 
the E2 subunits of the pyruvate dehydrogenase complex and 
related proteins.5,6 In fact, the target is restricted to lipoic acid 
modification of a specific lysine residue. Moreover, T-cell 
responses from both CD4+ and CD8+ cells are enhanced in 
both peripheral blood and liver of patients with PBC and 
are directed to the same epitopes. Genome-wide association 
studies have implicated a number of immune-related genes, 
including IL-12, in susceptibility to PBC.7 Both epidemio-
logic and experimental studies support the idea that envi-
ronmental exposures also play an important role in breaking 
tolerance to the self-antigens.6 Nevertheless, attempts at alter-
ing the natural history of PBC through immune modulation 
have to date been unsuccessful.8
Until recently, ursodeoxycholic acid (UDCA) was the 
only drug approved by the US Food and Drug Administration 
(FDA) for the treatment of PBC.9 UDCA was first shown to 
have favorable effects in patients with PBC in the 1980s,2 
and at a dose of 13–15 mg/kg/d, improves liver biochem-
istries, slows histological progression, and improves liver 
transplantation-free and overall survival, at least in those 
treated in the early stages of the disease.2,9,10 Because PBC 
is a rare and slowly progressive disease, individual clinical 
trials have lacked the power to demonstrate clinically mean-
ingful differences in outcomes in most cases. This limita-
tion has led to comparisons of the rates of actual clinical 
outcomes in patients treated with UDCA to predicted rates 
of outcomes based upon natural history models applied to 
the same population assuming that they had not been treated 
with UDCA. The updated Mayo natural history model for 
PBC is a validated prognostic model of liver transplant-free 
survival, and when applied to a cohort of PBC patients who 
had received 13–15 mg/kg UDCA daily for a mean of 8 years 
(range 1–22 years), a Markov model predicted a significantly 
better liver transplant-free survival with UDCA compared to 
the spontaneous survival rate predicted by the Mayo model.11 
While the overall survival rates without liver transplantation 
were 84% and 66% at 10 and 20 years, respectively, in early-
stage patients, only 6% and 22% were predicted to progress 
to liver transplantation or death after 10 and 20 years, respec-
tively. These survival rates were similar to that of an age- and 
sex-matched control population. In contrast, the probability 
of death or liver transplantation was significantly increased 
in patients treated in late stages of the disease.10
Other indicators of poor outcome despite UDCA 
treatment include an incomplete biochemical response to 
UDCA.12–14 Several studies have proposed various criteria as 
predictors of treatment success with UDCA.12,13,15–19 Studies 
of large patient cohorts from France and the United Kingdom 
demonstrated that reduction of the ALP and aspartate trans-
aminase (AST) to <1.5 × the upper limit of normal (ULN) 
and a normal total bilirubin after 1 year of UDCA therapy 
(Paris II criteria) was the best criterion for distinguishing 
high- and low-risk groups of patients.16,20 More recent studies 
of an international cohort of over 4,500 PBC patients further 
characterized the relationship between levels of serum ALP 
and total bilirubin at 1-year of follow-up and the risk of liver 
transplantation or death21 leading to the PBC GLOBE score, 
which incorporates age at initiation of UDCA therapy, levels 
of serum ALP, total bilirubin, albumin, and platelets (http://
www.globalpbc.com/globe).22 These studies have been criti-
cal to our understanding of the natural history of PBC in the 
era of UDCA and for the appropriate selection of patients 
for additional therapies, namely, obeticholic acid (OCA).
Obeticholic acid
In addition to their roles in the solubilization of lipids for 
digestion, bile acids (BAs) have more recently been found 
to act as signaling molecules, notably through the farnesoid 
X receptor (FXR), a nuclear receptor expressed in the liver, 
intestine, adrenal glands, and kidneys that has a central role in 
the synthesis and enterohepatic circulation of BAs.23 OCA is a 
derivative of chenodeoxycholic acid, the primary human BA, 
and is the natural ligand for FXR. OCA is approximately 100 
times more potent as an FXR ligand than chenodeoxycholic 
acid24 and demonstrates high selectivity with minimal activity 
to the another described BA receptor, G protein-coupled bile 
acid receptor 1 (GPBAR1 or TGR5). Activation of FXR in 
the liver reduces conversion of cholesterol to  BAs by down-
regulating the primary enzymes involved in BA synthesis, 
including cytochrome P450 7A1 (CYP7A1) and CYP8B1. 
BA toxicity in the liver is also reduced by increasing other 
BA-modifying enzymes and promoting the transport of 
BAs. By activating FXR in the ileum, OCA decreases BA 
reabsorption through downregulation of the apical sodium-
dependent BA transporter and increased expression of fibro-
blast growth factor 19, which in the liver also decreases BA 
synthesis through CYP7A1.25 Preclinical studies have also 
suggested that OCA may have antifibrotic properties26,27 and 
the potential to improve portal hypertension.28
Two Phase II studies and a pivotal Phase III study have 
been completed that have investigated the safety and efficacy 
of OCA in patients with PBC (Table 1). An international, 
Phase II, double-blind, placebo-controlled, dose–response 
study evaluated the effects of OCA on ALP, other liver 
enzymes, and safety in patients with PBC with persistently 
elevated ALP levels >1.5–10× the ULN while on a stable 
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dose of UDCA for at least 6 months.29 A total of 165 patients 
were randomized to placebo, OCA 10, 25, or 50 mg once 
daily for 12 weeks while continuing UDCA at the preenroll-
ment dose. Compared with the placebo group, the groups 
taking 10, 25, or 50 mg OCA had a greater mean percent 
decrease in their ALP (–23.7%±17.8%, –24.7%±17.9%, 
–21.0%±27.6%, respectively, vs 2.6%±12.5%, P<0.0001). 
Significant decreases in alanine transaminase (ALT) and 
gamma-glutamyl transpeptidase were also seen in all treat-
ment groups compared with placebo.
In a long-term safety extension (LTSE) of this study, 78 
PBC subjects were started on 10 mg daily and titrated every 
8 weeks to a maximum dose of 50 mg.30 Safety and efficacy 
assessments occurred at baseline, pre- and posttitration, 
and every 3 months. At 10 mg daily OCA, mean ALP levels 
decreased by 71 U/L (19%), and a further decrease of 23 U/L 
(9%) occurred after titration from 10 to 25 mg. Mean ALP 
values increased by 8 U/L (2%) with titration from 25 to 50 
mg. Pruritus worsened, or was reported as a new adverse 
effect (AE), following titration to 25 mg in 46% of patients 
and in 17% of patients after titration to 50 mg, suggesting 
that a dose at or below 25 mg might provide the best balance 
between efficacy and tolerability.
The efficacy of OCA as a monotherapy was also evaluated 
in a Phase II, international, double-blind, placebo-controlled 
study of OCA in patients with PBC and persistently elevated 
ALP levels (≥1.5–10× ULN) who had not been taking UDCA 
for at least 6 months.31 Fifty-nine patients received placebo, 
OCA 10 mg or 50 mg once daily for 12 weeks. The OCA 10 
mg group showed the greatest ALP decrease, from 3.9× ULN 
pretreatment to 1.9× ULN, at the end of the study.
Interim results of the only Phase III study of OCA, 
PBC OCA International Study of Eff icacy (POISE; 
NCT01473524), were the basis for the recent FDA’s con-
ditional approval of OCA for the treatment of PBC with 
an incomplete response to UDCA (Figure 1).32 The POISE 
trial is an international, multicenter, placebo-controlled, 
randomized clinical trial designed to study the safety and 
Table 1 Randomized controlled trials of OCA for the treatment of PBS
Phase Duration Inclusion OCA dose Participants (n) Primary endpoint
OCA monotherapy; mean % change in serum ALP
II 12 weeks ALP >1.5× ULN
No UDCA >6 months
Placebo 23 +0.4%
10 mg daily 20 –45%
50 mg daily 16 –38%
OCA + UDCA combination therapy; mean % change in serum ALP
II 12 weeks 1.5× ULN < ALP <10× ULN Placebo 38 –3%
10 mg daily 38 –34%
25 mg daily 48 –25%
50 mg daily 41 –21%
OCA + UDCA combination therapy; ALP <1.67× ULN (with >15% reduction from baseline) and normalization of bilirubin
III 12 months ALP ≥1.67× ULN ± total bilirubin  
>ULN and <2× ULN
Placebo 73 10%
5–10 mg titration 70 46%
10 mg 73 47%
Abbreviations: PBS, primary biliary cholangitis; OCA, obeticholic acid; ALP, alkaline phosphatase; ULN, upper limit of normal; UDCA, ursodeoxycholic acid.
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Figure 1 Primary and secondary end points of POISE trial comparing obeticholic acid 10 mg daily, 5 mg daily titrating to 10 mg daily, and placebo.
Abbreviations: POISE, PBC OCA International Study of Efficacy; OCA, obeticholic acid; ALP, alkaline phosphatase; ALT, alanine aminotransferase; PBO, placebo.
Hepatic Medicine: Evidence and Research 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
92
Bowlus
efficacy of once-daily OCA in PBC patients with an incom-
plete response to or unable to tolerate UDCA. The primary 
end point of the 12-month double-blind portion of the trial 
was a composite of an ALP level <1.67× ULN with a ≥15% 
reduction from baseline and a normal bilirubin level com-
pared to placebo. Two hundred and seventeen patients were 
randomized to daily doses of placebo, 10 mg OCA, or 5 mg 
OCA titrated to 10 mg OCA based on clinical response at 
6 months. The median UDCA dose was 15.3 mg/kg, and 
7% of patients were UDCA intolerant. All three treatment 
groups were well matched. The primary end point was 
met in an intention to treat analysis with response rates of 
10% in the placebo group compared to 47% in the 10 mg 
OCA group and 46% in the 5–10 mg OCA group (both 
OCA groups P<0.0001 vs placebo). The placebo group 
experienced a mean decrease in ALP from baseline of 5%, 
compared to a mean decrease of 39% in the 10 mg OCA 
dose group and 33% in the 5–10 mg OCA titration group 
(both OCA groups P<0.0001 vs placebo). In addition to 
the reduction in ALP, patients treated with either dose of 
OCA had a greater decrease in total bilirubin compared to 
placebo (–0.02 and –0.05, respectively, vs 0.12; P<0.001), 
suggesting that there was improvement in liver function. 
Furthermore, both OCA groups met prespecified second-
ary end points of clinical biomarkers, including gamma-
glutamyl transpeptidase, ALT, and AST as well as markers 
of inflammation. More than 95% of subjects completing 
the double-blind portion of the study were enrolled into 
an optional open-label, long term safety extension, which 
is ongoing
The most common AE of OCA in PBC is dose-related 
pruritus. Although pruritus is prevalent in PBC, there 
was a clear increase in frequency and severity of pruritus 
in patients treated with OCA compared to placebo. For 
example, in the Phase II study by Mason et al,33 pruritus 
was reported by 50% of subjects taking placebo compared 
to 47%, 85%, and 80% of subjects taking OCA 10, 25, 
and 50 mg, respectively. Both severity and discontinua-
tion rates were dose dependent. No subjects in the placebo 
group discontinued compared to discontinuation rates due 
to pruritus of 8%, 8%, and 24% in the 10, 25, and 50 mg 
OCA groups, respectively. In the long-term extension of 
this study30 in which 78 participants were started on 10 mg 
OCA and OCA dose was increased every 8 weeks, pruritus 
occurred in almost all patients (n=71, 91%) ranging from 
mild in 35% to moderate in 42% and severe in 23%. All 
other AEs occurred in <20% of patients. In the Phase II 
study of OCA as monotherapy,31 pruritus was again the 
most common AE with similar rates. However, in the LTSE 
phase of this trial, with mean exposure time to OCA of 
3.2 years, pruritus improved in severity with continued 
treatment despite the number of days of exposure being 
similar each year.34
In the POISE trial where the dose of OCA was further 
reduced, pruritus was again the most frequently reported AE 
associated with OCA treatment, but was mostly mild-moderate: 
(placebo: 38%, OCA 10 mg: 68%, OCA 5–10 mg titration: 
56%) with only 1% discontinuation due to pruritus in the 
OCA 5–10 mg arm vs 10% in OCA 10 mg arm. As noted, the 
response rate at 12 months was not significantly different in the 
OCA 5–10 mg arm compared to the 10 mg OCA arm. Thus, 
the recommended starting dose is 5 mg oral daily, with the con-
sideration of increasing the dose to 10 mg daily after 3 months 
depending upon tolerability and biochemical response.
In addition to pruritus, liver-related adverse events and 
reductions in high-density lipoprotein -cholesterol (HDL-C) 
have been observed. In a pooled analysis of the three placebo-
controlled trials in PBC, the exposure-adjusted incidence 
rates for all serious and otherwise clinically significant 
liver-related adverse reactions, and isolated elevations in 
liver biochemical tests, per 100 patient exposure years were 
5.2 in the OCA 10 mg group, 19.8 in the OCA 25 mg group, 
and 54.5 in the OCA 50 mg group compared to 2.4 in the 
placebo group. In the POISE trial, dose-dependent 20% 
and 9% reductions from baseline mean HDL-C levels were 
observed at 2 weeks in patients in the 10 and 5–10 mg titra-
tion arms, respectively, compared to 2% in the placebo arm. 
No significant further reductions were seen at month 12, with 
19% and 12% reductions from baseline mean HDL-C level 
in the 10 and 5–10 mg titration arms, respectively, compared 
to 2% in the placebo arm.
Clinical utility
OCA has clearly demonstrated the ability to induce changes 
in liver biochemistries that are associated with a lower risk of 
liver transplantation or death, but has not yet demonstrated 
a direct impact on clinical outcomes or quality of life. In 
addition, the changes in ALP and bilirubin have not been 
validated as surrogates to clinical end points in any PBC 
study. Nevertheless, there is a preponderance of evidence 
establishing their association with clinical outcomes and 
biologic plausibility, especially with bilirubin, to anticipate 
that reductions in ALP and total bilirubin will translate into 
improved clinical outcomes. Results of the ongoing COBALT 
trial35 will establish whether OCA impacts clinical outcomes 
and to what degree.
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In the clinic, most PBC patients will still be adequately 
treated with UDCA monotherapy and will not require the 
addition of OCA. However, the 20%–40% of PBC patients 
who do not have an adequate biochemical response to 
UDCA will be candidates for OCA. In addition, OCA is a 
new alternative for the small number of PBC patients who 
cannot tolerate UDCA.
Patient selection
According to the FDA, OCA is indicated for the treatment 
of PBC in combination with UDCA in adults with an “inad-
equate” response to UDCA, or as monotherapy in adults 
unable to tolerate UDCA. Although the POISE study had 
strict enrollment criteria and definition of an inadequate 
response, the FDA approval allows for clinical judgment by 
the physician in determining whether an individual patient has 
responded adequately to UDCA. In most cases, an inadequate 
response to UDCA may be defined by one that leaves a patient 
at greater risk of liver transplantation or death compared to 
an age- and sex-matched control population. Several criteria, 
including those already discussed, have been developed and 
validated for this purpose (Table 2). The Global PBC Score 
has the advantage of being based upon the largest cohort and 
provides a direct comparison to the survival rates of an age- 
and sex-matched population. In contrast, the Paris I criteria 
provides a simple 1–2–3 score based upon total bilirubin 
<1× ULN; AST <2 × ULN; and ALP <3 × ULN. However, 
in clinical practice, several factors in addition to biochemical 
response to UDCA should be kept in mind when consider-
ing OCA to PBC patients. These include factors that might 
lower the threshold for treatment, such as advanced fibrosis 
or younger age, and factors that might increase the threshold 
for treatment, including severe pruritus and cardiovascular 
risk factors.
In the POISE study, patients were required to have an 
ALP >1.67 × ULN (approximately 200 U) or a bilirubin 
>ULN and <2 × ULN either despite UDCA or intolerance 
to UDCA. However, the Global PBC Study Group analysis 
demonstrated that the risk of liver transplantation or death 
begins increasing even at an ALP > ULN. In addition, the 
impact on risk is even greater with total bilirubin elevations 
and starts at levels that are >0.5 × ULN, ie, even within the 
normal range. Thus, in a patient with an ALP > ULN but 
<1.67 × ULN, treatment with OCA might be considered 
particularly in a younger patient or a patient with advanced 
fibrosis or cirrhosis. In addition, treatment should be consid-
ered in any patient with a bilirubin above ULN.
Patients with the most advanced disease, ie, those with 
a total bilirubin >2 × ULN, portal hypertension, or a Model 
for End-stage Liver Disease score ≥15 were excluded from 
the POISE trial but may be those most likely to benefit 
from therapy. However, data on the use of OCA in this 
population do not exist. Although the COBALT study35 will 
include PBC patients with more advanced disease, patients 
with more advanced disease, that is, Child–Pugh Class B 
and C cirrhosis, will not likely qualify. In the absence of 
data, the current recommendation is to start OCA at 5 mg 
once “weekly” and increase the dosage as tolerated to a 
maximum dose of 10 mg twice weekly at least 3 days apart 
(OCALIVA36 package insert).
The most challenging patients to manage with OCA are 
likely to be those with baseline moderate-to-severe pruritus. 
Importantly, PBC patients with severe pruritus requiring cur-
rent or prior systemic treatments, such as BA sequestrants 
or rifampicin, were excluded from the POISE trial32 but may 
represent those at greatest needed. Aggressive and appropri-
ate management of this symptom will be critical to ensuring 
that OCA reaches its full potential in the treatment of PBC 
Table 2 Biochemical response criteria for PBS treated with ursodeoxycholic acid
ALP AST Bilirubin Albumin PLT Age
Barcelona ↓40% or normal NA NA NA NA NA
Paris I ≤3× ULN ≤2× ULN <ULN NA NA NA
Paris II ≤1.5× ULN ≤1.5× ULN <ULN NA NA NA
Toronto <1.67× ULN NA NA NA NA NA
UK-PBC scorea √ √ √ √ √ NA
Global PBC scoreb √ NA √ √ √ √
Notes: aUK-PBC risk scores = 1 − baseline survival functionexp(0.0287854 × (ALP12 × ULN – 1.722136304) – 0.0422873 × (((TA12 × ULN/10)–1) – 8.675729006) + 1.4199 × 
(ln(BIL12 × ULN/10) + 2.709607778) − 1.960303 × (ALB12 × LLN – 1.17673001) – 0.4161954 × (PLT12 × LLN – 1.873564875)), where baseline survivor function  =  0.982 
(at 5 years); 0.941 (at 10 years); 0.893 (at 15 years). Calculator available at http://www.uk-pbc.com/resources/tools/riskcalculator/. bGLOBE score = 0.044378 × age at start 
of UDCA therapy + 0.93982 × ln(BIL12 × ULN) + 0.335648 × ln(ALP12 × ULN) − 2.266708 × ALB12 × LLN − 0.002581 × PLT12 per 109/L + 1.216865. Calculator available 
at http://www.globalpbc.com/globe.
Abbreviations: PBS, primary biliary cholangitis; ALP, alkaline phosphatase; AST, aspartate aminotransferase; PLT, platelet count; NA, not applicable; ALP12, ALP after 12 
months treatment; ALT, alanine aminotransferase; TA12, AST or ALT after 12 months treatment; BIL12, total bilirubin after 12 months treatment; ALB12, albumin after 12 
months treatment; PLT12, platelet count after 12 months treatment; ULN, upper limit of normal; LLN lower limit of normal; UDCA, ursodeoxycholic acid.
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patients. The mechanisms of pruritus in cholestasis and the 
pruritus induced by OCA are not well understood. Despite 
the common use of sequestrants to reduce serum BA levels, 
there is little empiric evidence that these treatments are effec-
tive, and in fact, there is no correlation between serum BA 
levels and the severity of pruritus. Similarly, it is perplexing 
that while OCA appears to improve cholestasis, it worsens 
pruritus. According to the OCA package insert, the manage-
ment of intolerable pruritus with OCA should include antihis-
tamines or  BA-binding resins, dose reductions of OCA, or 
interruptions in OCA for up to 2 weeks. However, the use of 
antihistamines in cholestatic pruritus is not supported by any 
evidence and, typically, is only effective in sedating patients. 
BA-binding resins are poorly tolerated and must be separated 
from OCA and UDCA by at least 4 hours, often leading to 
reduced adherence. Dose reductions including alternate day 
dosing and “drug holidays” are likely to be the most effective 
and practical approach to dealing with pruritus. The use of 
rifampicin, sertraline, or naltrexone for the management of 
pruritus induced or worsened by OCA was not allowed in the 
POISE trial,32 and the safety and efficacy of these medications 
in this setting has not been established.
The impact of the effects of OCA on HDL-C and car-
diovascular risk is not known, and neither is it known how 
to optimally manage these changes. Hypercholesterolemia 
in PBC is common and typically is due to an increase in 
lipoprotein X, which is identified as HDL-C by standard 
clinical labs, but there does not appear to be an increased 
risk of cardiovascular disease in PBC patients. A 7-year 
prospective study of 312 PBC patients found no statisti-
cally significant difference in atherosclerotic death rates 
between PBC patients and an age- and sex-matched control 
group.37 Similarly, a study of 400 PBC patients followed 
up over 6.2 years found the incidence of cardiovascular 
events in PBC patients was similar to that of the general 
population.38 These findings are despite the fact that PBC 
is associated with a higher frequency of smoking compared 
to healthy controls. Small clinical trials in PBC patients 
have demonstrated that HMG-CoA reductase inhibitors 
(statins) are effective in lowering low-density lipoprotein-
cholesterol without any significant impact on HDL-C, and 
these in general have been well tolerated. In PBC patients 
with advanced disease and without cardiovascular risk fac-
tors, the reductions in HDL-C are unlikely to be clinically 
significant. In PBC patients with higher cardiovascular risk 
factors or a history of cardiovascular disease, the risk–benefit 
analysis becomes much more difficult, especially in those 
with early-stage disease.
Conclusion
In April 2016, the US FDA granted accelerated approval 
of OCA for the treatment of PBC in combination with 
UDCA in adults who fail to respond adequately to UDCA, 
or as monotherapy in adults who cannot tolerate UDCA. In 
these patients, OCA has demonstrated that it improves ALP 
and other liver biochemistries, which are associated with 
improvements in long-term clinical outcomes. The long-term 
efficacy of OCA still needs to be delineated, and its clinical 
benefit on overall or transplant-free survival may be difficult 
to establish, given the slow progressive nature of the disease, 
rarity of the condition, and ethical concerns of carrying out 
a placebo-controlled trial now that OCA is approved for 
use in these patients. Tolerability in PBC patients who have 
baseline severe pruritus might limit its use in these patients 
unless appropriate management steps are taken, most likely 
with dose adjustments. Nevertheless, OCA offers the first new 
treatment for PBC in decades and the potential to slow the 
progression in the group of patients at greatest need. Patient 
selection will require individual assessment of the risk of 
disease progression to liver transplant and death, which can 
be predicted accurately with the GLOBE score, response to 
UDCA, cardiovascular risk factors, and baseline pruritus.
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